Unlike other studies reporting a reduction in the hepatic enzymes ALT, AST, or GGT [13,14,15,16,17,18,19,20], after the supplementation of n-3 PUFA, we found a reduction in the levels of ALP, which is commonly used as a marker of hepatobiliary and bone diseases [39,40], and has recently been described as an independent predictor of NAFLD in older women [41]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.